Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Result of AGM

The neuroscience company Cambridge Cognition Holdings plc (AIM: COG), which develops and markets products and near patient technologies for cognitive assessment in clinical trials and healthcare applications held its Annual General Meeting yesterday at 11.00am at the registered office of the Company, Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU. All resolutions were duly passed.

At the meeting Steven Powell, Chief Executive Officer, provided shareholders with the following update:

 "As we outlined in our Preliminary Results statement, we intend to accelerate revenue growth in both the academic research and pharmaceutical clinical trials business this year. We plan to achieve this through;

1). Investment in commercial infrastructure,

2). The launch of our online and wearable product platforms and

3). The introduction of partner products to maximise our sales channels exemplified by the recent announcements relating to the AnthroTronix DANA product and the MANUS pen for Parkinson's assessment.

We have made significant progress in the first half of 2016 towards implementation of our plan and we remain confident in the outlook for the year."

Enquiries: